(Press-News.org) SAN ANTONIO (June 30, 2021) -- In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
Among the 131 patients studied, 94% developed antibodies to the coronavirus. Seven high-risk patients did not. "We could not find any antibodies against the virus in those patients," said Dimpy P. Shah, MD, PhD, of the Mays Cancer Center, home to UT Health San Antonio MD Anderson. "That has implications for the future. Should we provide a third dose of vaccine after cancer therapy has completed in certain high-risk patients?"
Dr. Shah is corresponding author of the study, published in the high-impact journal Cancer Cell. Coauthors are from the Mays Cancer Center and the University of Geneva.
"With other vaccines and infections, patients with cancer have been shown not to develop as robust an immune response as the general population," said study senior coauthor Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center. "It made sense, therefore, to hypothesize that certain high-risk groups of patients do not have antibody response to COVID-19 vaccine."
"Patients with hematological malignancies, such as myeloma and Hodgkin lymphoma, were less likely to respond to vaccination than those with solid tumors," said Pankil K. Shah, MD, PhD, of the Mays Cancer Center, who served as co-lead author of the study with Alfredo Addeo, MD, senior oncologist at the Geneva University Hospital.
Among the high-risk groups, patients receiving a therapy called Rituximab within six months of vaccination developed no antibodies. Rituximab is a monoclonal antibody used in the treatment of hematological cancers and autoimmune diseases.
Patients on chemotherapy that is toxic to cells developed antibody response, but it was muted compared to the general population. "How that relates to protection against COVID-19, we don't know yet," Dr. Dimpy Shah said.
The Delta variant and other mutants of the COVID-19 virus were not examined in the study. The team also did not analyze the response of infection-fighting T cells and B cells in the patients with cancer.
The median age of patients in the study was 63. Most of the patients (106) had solid cancers as opposed to hematological malignancies (25). The study population was 80% non-Hispanic white, 18% Hispanic and 2% Black.
"We recommend that future studies be done in Black, Asian and Hispanic patients, as well, to see if there are any differences in vaccination immune response," Dr. Mesa said.
In countries where there is lack of vaccination, there is talk that one dose might confer adequate protection, but this may not be true in the case of patients with cancer, Dr. Dimpy Shah said.
"We observed a significant difference in response when two doses were given," Dr. Shah said. "At least for patients with cancer, two doses are very important for robust antibody response."
Dr. Pankil Shah said the study is unique because, unlike a few studies conducted in the past that evaluated immune response on the day of the second dose or within seven days of it, this study waited three to four weeks to obtain results.
Patients with high-risk cancers, especially those receiving anti-CD20 antibodies, should continue to take precautions even after being vaccinated, the study implies. "They still need to have that awareness that they could potentially be at risk because their body has not responded to vaccination," Dr. Pankil Shah said.
INFORMATION:
This research was made possible, in part, by a U.S. National Cancer Institute grant to the Mays Cancer Center and a grant from the American Cancer Society and the Hope Foundation for Cancer Research.
Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer
Alfredo Addeo, Pankil K. Shah, Natacha Bordry, Robert D. Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, Pierre-Yves Dietrich, Barbara S. Taylor, Pierre-Francois Simand, Darpan Patel, Jing Wang, Intidhar Labidigaly, Sarah Fertani, Robin J. Leach, Jose Sandoval, Ruben Mesa, Kate Lathrop, Nicolas Mach, Dimpy P. Shah
First published: June 18, 2021, Cancer Cell
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00330-5
The Mays Cancer Center, home to UT Health San Antonio MD Anderson, is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. Visit www.UTHealthsaMDAnderson.org.
To see how we are battling COVID-19, read inspiring stories on Impact.
Expanding symptom list in line with other countries could improve the UK's pandemic response
The UK should expand its official list of symptoms for defining covid-19 to prevent cases being missed and help improve the UK's pandemic response, say experts in The BMJ today.
They argue that limiting symptomatic testing to those with these official symptoms "will miss or delay identification of many covid-19 cases, hampering efforts to interrupt transmission."
During the covid-19 pandemic the British public has been told to self-isolate and get a test if they have a high fever, a new continuous cough, or ...
Eating a diet rich in omega 3 (n-3) fatty acids reduces the frequency of headaches compared with a diet with normal intake of omega 3 and omega 6 (n-6) fatty acids, finds a study published by The BMJ today.
Modern industrialised diets tend to be low in omega 3 fatty acids and high in omega 6 fatty acids. These fatty acids are precursors to oxylipins - molecules involved in regulating pain and inflammation.
Oxylipins derived from omega 3 fatty acids are associated with pain-reducing effects, while oxylipins derived from omega 6 fatty acids worsen pain and can provoke migraine. But previous studies evaluating omega 3 fatty acid supplements for migraine have been inconclusive.
So a team of US researchers wanted to find out whether diets ...
A diet higher in fatty fish helped frequent migraine sufferers reduce their monthly number of headaches and intensity of pain compared to participants on a diet higher in vegetable-based fats and oils, according to a new study. The findings by a team of researchers from the National Institute on Aging (NIA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), parts of the National Institutes of Health; and the University of North Carolina (UNC) at Chapel Hill, were published in the July 3 issue of The BMJ.
This study of 182 adults with frequent migraines ...
New research being presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held online (9-12 July) identifies drugs that could potentially be repurposed for the treatment of gonorrhoea (Neisseria gonorrhoeae [Ng]): a sexually transmitted infection which is becoming increasingly resistant to existing antibiotics.
The decreased susceptibility of the Ng bacterium to extended spectrum cephalosporin antibiotics has become an important public health issue as cases of this common infection become more difficult to treat.
The study ...
New research presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) taking place online (9-12 July) shows that individuals affected by mental illnesses including depression and schizophrenia experience an increased incidence of tuberculosis (TB).
TB and mental illnesses are both urgent global health priorities with a high prevalence across the world, and often co-exist. Although poor mental health is known to affect the immune system, it is not known whether mental illness plays a causal role in TB infection ...
COVID-19 is common in pet cats and dogs whose owners have the virus, according to new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
Cases of owners spreading the disease to their dog or cat have been documented before but are considered to be of negligible risk to public health. However, as vaccination and other measures reduce human-to-human transmission of the virus, it is becoming imperative that we understand more about the potential risk posed by animal infections.
To find out more, Dr Els Broens ...
**Note this is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2021). Please credit the conference if you use this story**
New research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held online this year, suggests that people with COVID-19 frequently pass it on to their pets. Cats that sleep on their owner's bed seem to be at particular risk of infection.
Previous studies have shown that cats and dogs can catch COVID-19 from their owners but it wasn't clear how susceptible they were and what, if anything, increased their odds of becoming infected. Answering these questions is important from both a public health and animal ...
Individuals who contract COVID-19 even after vaccination are likely to have a lower viral load, experience a shorter infection time and have milder symptoms than people who are unvaccinated, according to research that includes data from ongoing University of Arizona Health Sciences studies.
"If you get vaccinated, about 90% of the time you're not going to get COVID-19," said Jeff Burgess, MD, MS, MPH, associate dean for research and professor at the Mel and Enid Zuckerman College of Public Health and principal investigator of the Arizona Healthcare, ...
MINNEAPOLIS - Finding treatments for advanced multiple sclerosis (MS) has been difficult. But new research may help neurologists identify which drugs are best for people with the advanced form of MS called secondary progressive MS. The new study, published in the June 30, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology, found that the more potent disease-modifying drugs are more effective in reducing flare-ups in secondary progressive MS than the less potent drugs that tend to be safer to take. However, the researchers found no difference in how fast the disease progressed between these two types of drugs.
Most ...
MINNEAPOLIS - A new study suggests that even when differences in socioeconomic status are taken into consideration, Black people with multiple sclerosis (MS) may be more negatively impacted by the disease than white people with MS. The research is published in the June 30, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study found that Black people with MS had lower scores on certain measures of neurological health, like dexterity and walking tests and showed more evidence of disease progression on brain scans.
"While lower socioeconomic status appears to be linked to doing worse on tests ...
